The three-year grant to Korean chemical company LG Chem will be used to advance clinical trials on a new inactivated polio vaccine....
NYS Entity Status
NYS Filing Date
JULY 15, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC NOT-FOR-PROFIT CORPORATION
2014 - ADVANCED CLINICAL EDUCATION FOUNDATION OF THE NEW YORK STATE SOCIETY FOR CLINICAL SOCIAL WORK, INC.
AROUND THE WEB
- Gates Foundation Awards $12.6 Million for Polio Vaccine Research
By firstname.lastname@example.org (Matt Sinclair) - Sunday Jun 11, 2017
- Cleveland Clinic Receives $10 Million for Expansion of Eye Institute
By email@example.com (Mitch Nauffts) - Monday Jun 5, 2017
The gift from the Timken Foundation of Canton will support an expansion of the Cole Eye Institute and the creation of the Louise Timken Ophthalmic Education Center....
- Bio Roundup: ASCO Digested, Juliet Unveiled, PTC Slated & More
By Alex Lash - Friday Jun 9, 2017
The New York Times Magazine wrote a few weeks ago about the extraordinary metabolic changes in a python after it gulps down a 50,000 calorie meal. The biomedical world was like a postprandial python this week; after extending its maw around the supersized meal of news and data from the American Society for Clinical Oncology […]
- FDA Halts Merck’s Multiple Myeloma Trials After Patient Deaths
By Frank Vinluan - Wednesday Jul 5, 2017
Nearly a month after Merck paused enrollment in three clinical trials in multiple myeloma to gather more information about patient deaths, the FDA has now put a stop to those studies altogether. Merck (NYSE: MRK) said Wednesday that the FDA has placed a complete hold on two Phase 3 trials testing its immunotherapy drug pembrolizumab […]
- Precision Steps: Can Loxo Drug Help Broaden Use of Cancer DNA Tests?
By Ben Fidler - Saturday Jun 3, 2017
When the FDA last week approved Merck’s cancer drug pembrolizuamb (Keytruda) for tumors with a specific genetic signature, regardless of what body part they originated in, it was a watershed moment for oncology and a victory for the concept of precision medicine. But Merck isn’t alone; others are following suit with similar plans, and their […]
- Teva Seeks to Keep Pace in Migraine Drug Race With Trial Results
By Frank Vinluan - Wednesday May 31, 2017
An experimental Teva Pharmaceutical migraine drug has met the main goals of a late-stage clinical trial, keeping the drugmaker in the race to bring to the market a product that prevents migraine headaches instead of treating them after they start. Teva (NYSE: TEVA) reported Wednesday that its drug fremanezumab reduced the number of days during […]